Xeris Biopharma (NASDAQ:XERS) Price Target Raised to $6.50

Xeris Biopharma (NASDAQ:XERS) had its price target hoisted by Craig Hallum from $5.00 to $6.50 in a report released on Friday morning,Benzinga reports. Craig Hallum currently has a buy rating on the stock.

Several other equities analysts have also commented on XERS. HC Wainwright reissued a “buy” rating and set a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a research report on Friday. Jefferies Financial Group reiterated a “buy” rating and set a $6.00 price objective (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Finally, Piper Sandler restated a “neutral” rating and issued a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a research note on Friday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $5.90.

Xeris Biopharma Stock Performance

XERS opened at $4.24 on Friday. Xeris Biopharma has a 1 year low of $1.69 and a 1 year high of $4.50. The firm has a 50 day moving average price of $3.57 and a 200 day moving average price of $3.26. The company has a market cap of $632.10 million, a PE ratio of -9.42 and a beta of 2.32.

Hedge Funds Weigh In On Xeris Biopharma

Several hedge funds have recently made changes to their positions in XERS. Vanguard Group Inc. boosted its position in shares of Xeris Biopharma by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company’s stock valued at $26,778,000 after purchasing an additional 133,738 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Xeris Biopharma by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company’s stock worth $11,364,000 after buying an additional 17,956 shares during the period. AIGH Capital Management LLC boosted its holdings in shares of Xeris Biopharma by 17.8% in the fourth quarter. AIGH Capital Management LLC now owns 2,574,846 shares of the company’s stock worth $8,729,000 after buying an additional 389,192 shares during the period. Renaissance Technologies LLC increased its position in shares of Xeris Biopharma by 31.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company’s stock worth $7,115,000 after acquiring an additional 500,120 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Xeris Biopharma by 34.8% during the fourth quarter. Millennium Management LLC now owns 1,948,552 shares of the company’s stock valued at $6,606,000 after acquiring an additional 502,853 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.